Presentation Theater #2: Reduce Cardiovascular Risk with VASCEPA (icosapent ethyl): Evidence from REDUCE-IT

Description

Despite the benefits of LDL-C lowering, many patients on statin therapy with elevated triglycerides remain at risk for cardiovascular disease. The unprecedented data from the VASCEPA cardiovascular outcomes trial, REDUCE-IT, and its potential impact on patient care is evaluated.

Speaker: Daniel E. Hilleman, PharmD, FCCP

Presented by Amarin Pharma, Inc.

 
 
 
Interest: Presentation Theater
Session Time Slot(s): 
Date: 
Sunday, March 24
Time: 
1:30 PM - 2:30 PM
Room: 
Washington State Convention Center - Hall EF